
1. Virus Res. 2021 Nov 12;308:198629. doi: 10.1016/j.virusres.2021.198629. [Epub
ahead of print]

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2
B.1+L249S+E484K lineage.

Álvarez-Díaz DA(1), Laiton-Donato K(1), Torres-García OA(2), Ruiz-Moreno HA(1),
Franco-Muñoz C(3), Beltran MA(4), Mercado-Reyes M(1), Rueda MG(4), Muñoz AL(5).

Author information: 
(1)Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en
Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.
(2)Faculty of Veterinary Medicine and Zootechnics, Universidad Antonio Nariño,
Bogotá, Colombia.
(3)Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en
Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia; Grupo de
Parasitología, Dirección de Investigación en Salud Pública, Instituto Nacional de
Salud, Bogotá, Colombia.
(4)Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia.
(5)Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia; Faculty of
Science, Universidad Antonio Nariño, Calle 23 #116-31, Bodega 26, Bogotá,
Colombia. Electronic address: ana.munoz@hemolfeamerica.org.

The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in
different variants around the world and has been widely associated with immune
escape from neutralizing antibodies generated during previous infection or
vaccination. In this work, the B.1 + L249S+E484K lineage was isolated along with 
A.1, B.1.420, and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the 
neutralizing titer of convalescent sera was compared using microneutralization
assays. While no significant differences in the neutralizing antibody titers were
found between A.1 and B.lineages without the E484K mutation, the neutralizing
titers against B.1 + L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than
against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular
epidemiological data indicate that there is no increase in the transmissibility
rate associated with this new lineage. This study supports the capability of new 
variants with the E484K mutation to be resistant to neutralization by humoral
immunity, and therefore the need to intensify surveillance programs to determine 
if these lineages represent a risk for public health.

Copyright © 2021. Published by Elsevier B.V.

DOI: 10.1016/j.virusres.2021.198629 
PMCID: PMC8585963
PMID: 34780883 

